Efficacy of sarcopenia treatment in patients with type 2 diabetes mellitus

Recruiting

Recruitment & Eligibility

Inclusion Criteria

Patients 65 years of age or older at the date of enrollment
Patients who meet the following sarcopenia diagnostic criteria (based on AWGS2019) Grip strength: 28 kg or less in men and 18 kg or less in women SMI (musculoskeletal index) measured by InBody: 7.0 kg/m2 or less in men and 5.4 kg/m2 or less in women.
Patients whose blood samples taken within 2 weeks prior to enrollment meet the following criteria 8.0% > HbA1c > 6.5
Patients who provide written consent for participation in the study

Exclusion Criteria

Patients with hyperglycemic emergencies, severe infections, major surgeries, or serious trauma within the past 6 months
Patients scheduled for surgery within the next 3 months
Patients who have already received prescriptions for EPA, EPA/DHA, or BCAA preparations
Patients with a history of allergy to EPA, EPA/DHA, or BCAA preparations in the past
Patients with bleeding (blood disease, active gastrointestinal ulcer, vitreous hemorrhage, etc.)
Patients with inborn errors of metabolism of branched-chain amino acids
Patients who are judged to be inappropriate as research subjects by the investigator(s), such as those who have difficulty in outpatient visits, those who are unlikely to be able to receive a certain intensity of rehabilitation.

Primary Outcome Measures

Name	Time	Method
-		Change in skeletal muscle index

Secondary Outcome Measures

Name	Time	Method